Dana-Farber has played a foundational role in more than half of the cancer drugs approved by the FDA.
Data from 2018-2022
What we learn about cancer in the lab we turn against cancer in the clinic, and vice versa. These discoveries ripple across the cancer landscape.
-
BCL-2 INHIBITORS
Anthony G. Letai, MD, PhD
Jacqueline S. Garcia, MDvideo
-
PD-L1 AND CTLA-4 PATHWAYS
F. Stephen Hodi, Jr., MD
Gordon J. Freeman, PhDvideo
-
NOBEL PRIZE WINNING RESEARCH
William G. Kaelin Jr., MD
video
-
CDK4/6 INHIBITORS
Geoffrey Shapiro, MD, PhD
Peter Sicinski, MD, PhD
Erica L. Mayer, MD, MPHaudio
-
PROTEIN DEGRADATION
Benjamin L. Ebert, MD, PhD
Kenneth C. Anderson, MD
Eric Fischer, PhDaudio
What we do here
changes lives everywhere
When you follow the science, one thing leads to another. A new insight takes a previous breakthrough further. Thanks to our momentum of discovery, living with cancer is less of a burden, and living without cancer is a greater possibility.
One cancer discovery after another for over 75 years.
